PDCD1 (programmed cell death 1; HGNC:8760, NCBI Gene ID 5133) is a human locus mapped to chromosome band 2q37.3 that encodes inhibitory T-cell co-receptor PD-1 / CD279 (288 aa). PDCD1 acts in SHP-2 phosphatase recruitment & attenuation of TCR/CD28 signaling for peripheral tolerance, together with PD-1 Receptor Pharmacology, CTLA4 (CTLA-4 Immune Checkpoint Gene), and CRISPR-Cas9 Genome Editing. Encodes the PD-1 inhibitory immune checkpoint receptor on activated T cells, targeted by cancer immunotherapies and CRISPR-edited CAR-T cells.
SHP-2 phosphatase recruitment & attenuation of TCR/CD28 signaling for peripheral tolerance
Clinical / Therapeutic Role
Target of Nobel-winning checkpoint blockade antibodies (pembrolizumab, nivolumab) & ex vivo CRISPR knockout in CAR-T cells
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 5-exon gene at chromosome 2q37.3 transcriptionally induced upon T-cell receptor stimulation by NFATc1, AP-1, Notch, and chronic interferon/STAT3-4 signaling, encoding an extracellular IgV-like ligand-binding domain, a transmembrane helix, and a cytoplasmic tail bearing both an immunoreceptor tyrosine-based inhibitory motif (ITIM, Tyr223) and an immunoreceptor tyrosine-based switch motif (ITSM, Tyr248).
Cellular & Tissue Expression Profile: Induced on activated CD8+ cytotoxic and CD4+ helper T lymphocytes, follicular helper T cells, regulatory T cells, B lymphocytes, and natural killer cells, with sustained high expression defining exhausted tumor-infiltrating T lymphocytes (TILs).
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Upon binding its ligands PD-L1 (CD274, expressed on hematopoietic, endothelial, and tumor cells) or PD-L2 (PDCD1LG2), the cytoplasmic ITSM and ITIM motifs are phosphorylated by Lck/Src kinases and recruit the tyrosine phosphatase SHP-2 (PTPN11), which dephosphorylates the CD28 co-stimulatory receptor and ZAP70/CD3-zeta to halt PI3K-AKT and RAS-ERK T-cell proliferation and cytokine secretion.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Regulatory polymorphisms in PDCD1 (such as PD-1.3 in intron 4 disrupting a RUNX1 binding site) are associated with susceptibility to systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes, while tumors exploit PD-L1 up-regulation to evade cytotoxic T-cell destruction.
Therapeutic & Clinical Pharmacology: Discovered by Tasuku Honjo (2018 Nobel Prize in Physiology or Medicine); targeted by FDA-approved anti-PD-1 monoclonal antibodies (pembrolizumab, nivolumab, cemiplimab, dostarlimab) across >25 cancer types, and routinely knocked out ex vivo via multiplex CRISPR-Cas9 ribonucleoproteins in next-generation adoptive CAR-T and TCR-T cell therapies to prevent T-cell exhaustion.